Print Page   |   Sign In   |   Become a Member
Site Search
News from the Field
Blog Home All Blogs
Search all posts for:   

 

News from the Field: April 2018

Posted By Connections Editor, Friday, April 13, 2018
Updated: Wednesday, April 11, 2018
A breakthrough in our understanding of how red blood cells develop
 
New Data Confirms Role of Residual Disease in AML Relapse
 
Hematopoiesis in the Bone Marrow Microenvironment: Of Cells, Their Interactions, and Therapeutic Opportunities

 

This post has not been tagged.

Share |
PermalinkComments (0)
 

New From the Field - March 2018

Posted By Connections Editor, Wednesday, March 21, 2018
From haematopoietic stem cells to complex differentiation landscapes

Retracing a Blood Cell's Fate
 
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
 
FDA grants priority review for AML drug
 
5 Immuno-Oncology Developments To Watch In 2018

This post has not been tagged.

Share |
PermalinkComments (0)
 

News From the Field - November/December 2017

Posted By Connections Editor, Wednesday, November 15, 2017
FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A
Biomarin

Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
Novartis

Six papers by disgraced surgeon should be retracted, report concludes
Science
 
Omeros Reports Additional and Consistently Positive Data for OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros Press Release

This post has not been tagged.

Share |
PermalinkComments (0)
 

News from the Field: August 2017

Posted By Connections Editor, Monday, August 28, 2017

CRI scientists discover vitamin C regulates stem cell function and suppresses leukemia development
UT Southwestern Medical Center

Getting instructions from mum
Nature Reviews Genetics

The rise of unproven stem cell therapies turned this obscure scientist into an industry watchdog
Science

 

Human AML xenograft with FLT3 mutation shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition with tumor regression
Press Release

 

 

This post has not been tagged.

Share |
PermalinkComments (0)
 

News from the Field: June 2017

Posted By Administration, Tuesday, June 20, 2017

This post has not been tagged.

Share |
PermalinkComments (0)
 

News from the Field: April 2017

Posted By Connections Editor, Friday, April 21, 2017

French-election fears unite scientists in defence of liberal democracy
Nature

Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Press Release

 

Scientists Use CRISPR-Cas9 to Create Red-Eyed Mutant Wasps
Sci News

 

Global Leukemia Therapeutics Market will reach USD 11.97 Billion by 2022: Zion Market Research

Globe NewsWire (Nasdaq)

 

This post has not been tagged.

Share |
PermalinkComments (0)
 

News from the Field: December 2016

Posted By Connections Editor, Thursday, December 15, 2016
Share |
PermalinkComments (0)
 

News from the Field: October 2016

Posted By Connections Editor, Tuesday, November 1, 2016
TLC178 Granted Orphan Drug Designation by US FDA for the Treatment of Cutaneous T-Cell Lymphoma

TLC announced that product candidate TLC178 has been granted an orphan drug designation for the treatment of cutaneous T-cell lymphoma by the U.S. Food and Drug Administration (FDA). [Taiwan Liposome Company, Ltd.] 

 

Northwestern Mutual Announces $900,000 in New Childhood Cancer Research Grants

Northwestern Mutual, through its Foundation, announced the funding of six new grants supporting childhood cancer research. The causes of most childhood cancers are unknown, and for the most part these cancers cannot be prevented. The grants, distributed through Alex's Lemonade Stand Foundation's Young Investigator Program, are designed to support scientists early in their research careers. [Northwestern Mutual]

Two Major California Research Institutes Will Merge

One of the biggest nonprofit biomedical research outfits in the world is getting a new translational medicine research arm, aimed at speeding the conversion of basic research insights into novel medicines. Officials at the Scripps Research Institute announced that it will merge with the California Institute for Biomedical Research, which was launched in 2012 as a nonprofit version of a drug development company. [ScienceInsider]

This post has not been tagged.

Share |
PermalinkComments (0)
 

News from the Field: August 2016

Posted By Connections Editor, Friday, August 19, 2016

US grants for zebrafish studies on the rise
Zebrafish are the rising stars of model-organism research, an analysis of grants from the US National Institutes of Health (NIH) shows. A team at the NIH Office of Portfolio Analysis assessed trends in the agency’s funding of model-organism research between 2008 and 2015, through its R01 awards, the largest NIH grant program for individual investigators. [Nature]  

 

The Bulk of the Hematopoietic Stem Cell Population Is Dispensable for Murine Steady-State and Stress Hematopoiesis
Scientists depleted hematopoietic stem and progenitor cells in adult mice in situ and found that long term repopulating hematopoietic stem cells recovered from initially very low levels to below 10% of normal numbers but not more, while progenitor cells substantially recovered shortly after depletion. [Blood]

Increased Hematopoietic Activity in Patients with Atherosclerosis

Considering the chronic low-grade inflammatory state in atherosclerosis, the authors hypothesized that hematopoietic hyperactivity is a persistent feature in cardiovascular disease. They aimed to assess the activity of hematopoietic organs and hematopoietic stem and progenitor cells in humans. [Eur Heart J]

Kiadis Pharma’s Orphan Drug Designation for ATIR101™ Further Expanded to Include Treatment in a Hematopoietic Stem Cell Transplantation

Kiadis Pharma N.V. announced that its lead product, ATIR101™, has been granted an expansion to its existing Orphan Drug Designation by the European Medicines Agency to include treatment in a hematopoietic stem cell transplantation. [Kiadis Pharma N.V.]

Actinium Pharmaceuticals Initiates Pivotal Phase III SIERRA Trial

Actinium Pharmaceuticals, Inc. announced that the pivotal Phase III clinical trial for Iomab-B has been initiated. Iomab-B upon approval, is intended to be an induction and conditioning agent used to prepare patients with relapsed or refractory AML who are over the age of 55 for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. [Actinium Pharmaceuticals, Inc.]

This post has not been tagged.

Share |
PermalinkComments (0)
 

New from the Field

Posted By Connections Editor, Thursday, June 16, 2016
BloodCenter of Wisconsin and San Diego Blood Bank Announce Collaborative Offering Called Celluvative
BloodCenter of Wisconsin and the San Diego Blood Bank have created a strategic partnership to accelerate advancements in research and patient care. [Celluvative]

GlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia
GlycoMimetics, Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-selectin antagonist GMI-1271 for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and elderly patients aged 60 years or older with AML. [GlycoMimetics, Inc.]

Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
Galena Biopharma, Inc. announced that combined safety data from the Company’s GALE-401 clinical trials were presented. [Press release from Galena Biopharma, Inc. discussing research presented at the European Hematology Association 21st Congress, Copenhagen]

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
Seattle Genetics, Inc. highlighted data evaluating vadastuximab talirine in combination with hypomethylating agents in frontline patients with acute myeloid leukemia who had declined intensive therapy. [Press release from Seattle Genetics discussing research presented at the European Hematology Association 21st Congress, Copenhagen]

Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase III Trial in High-Risk Acute Myeloid Leukemia
Celator Pharmaceuticals, Inc. announced positive response rate results in acute myeloid leukemia patients with FLT3 (FMS-like tyrosine kinase-3) mutation were presented. [Press release from Celator Pharmaceuticals, Inc. discussing research presented at the European Hematology Association 21st Congress, Copenhagen]

New Approach Could Make Bone Marrow Transplants Safer
Researchers developed a non-toxic transplantation procedure using antibodies to specifically target blood stem cells in mice, an approach they hope will make blood stem cell transplants for these patients far less toxic. [Press release from Harvard Stem Cell Institute discussing online prepublication in Nature Biotechnology]

This post has not been tagged.

Share |
PermalinkComments (0)
 
Page 1 of 3
1  |  2  |  3
Association Management Software Powered by YourMembership  ::  Legal